PV Bulletin

Online Peptides: Do Not Use, They Can Be Dangerous

The ANSM warns against the dangers of peptides sold online, specifically targeting illegal products such as FastPen 40 mg containing retatrutide.

Primary source: PUBLIÉ LE 19/11/2025 - MIS À JOUR LE 31/08/2026 L’ANSM prend des mesures de police sanitaire à l’encontre des sites inte

Translated From French

PV Bulletin does not take any responsibility for translation errors or omissions, though it has used the best available translation engine.

PV Impact Brief

Urgency: HighConfidence: high

What changed

Implementation of health police measures on 31/08/2026 against the illegal sale of products presented as aGLP-1, specifically targeting FastPen 40 mg as containing retatrutide.

Why it matters

This warning reflects significant safety signals related to unauthorized peptides, which pose serious health risks to consumers, informing risk management and the need for enhanced safety practices.

Action needed

Increased vigilance and reporting obligations on illegal peptide products, with an emphasis on monitoring and managing safety signals pertaining to these substances.

Relevant for
Regulatory Intelligence Lead
Processes impacted
Signal Management
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Evidence and confidence

Confidence: highSource updated: Aug 31, 2026

Full briefing

Practical implication

Increased vigilance and reporting obligations on illegal peptide products, with an emphasis on monitoring and managing safety signals pertaining to these substances.

The ANSM has issued a warning regarding peptides sold online, particularly those falsely presented as aGLP-1. This includes new health police measures introduced on 31/08/2026, aimed at banning illegal sales of these potentially harmful substances. Retatrutide-containing FastPen 40 mg is specifically highlighted as a concern due to significant health risks associated with its use.

What changed: Implementation of health police measures on 31/08/2026 against the illegal sale of products presented as aGLP-1, specifically targeting FastPen 40 mg as containing retatrutide.

Why it matters: This warning reflects significant safety signals related to unauthorized peptides, which pose serious health risks to consumers, informing risk management and the need for enhanced safety practices.

Practical implication: Increased vigilance and reporting obligations on illegal peptide products, with an emphasis on monitoring and managing safety signals pertaining to these substances.

View original source

  • Source: ANSM (France) - News feed
  • Published at source: 2026-08-31T00:00:00.000Z
  • Discovered by monitor: 2026-08-31T21:32:58.817Z

Published from the regulator source ingestion pipeline after PV impact triage.

#Safety Signal#Safety Signals#Source-ingestion#Regulator-monitor#Translated From French#France#Ansm.sante.fr

Related updates for your role

publicFDA · USA · Updated Sep 1, 2026

Breathing Circuit Recall: Medline Removes Neonatal and Infant Heated Wire Breathing Circuits

Urgency: High

Healthcare providers and distributors must immediately identify and quarantine affected products before destroying them after completing the recall actions. Compliance with FDA recall procedures is mandatory.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Latest
Read impact briefarrow_forward
publicEuropean Medicines Agency · European Union · Updated Aug 31, 2026

List of centrally authorised products with safety-related changes to the product information

Urgency: High

Review and update labeling processes in accordance with the newly published safety-related changes for affected products.

LabelingLabeling Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Labeling Lead, Regulatory Intelligence Lead
verifiedRegulatory action: Latest
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Aug 31, 2026

Guidance for industry on implementing Shortage Prevention Plans (SPP)

Urgency: High

MAHs must allocate resources to develop and maintain SPPs, ensuring they meet the new regulatory requirements and are ready for submission within two days upon request in crisis situations.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Latest
Read impact briefarrow_forward
publicFDA · USA · Updated Aug 31, 2026

FDA Approves Treatment for Essential Thrombocythemia

Urgency: High

Implementation of new dosing schedules and an emphasis on monitoring for potential adverse reactions as outlined in the prescribing information.

LabelingRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Labeling Lead
verifiedRegulatory action: Latest
Read impact briefarrow_forward